# Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma

> **NCT00089219** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Virginia** · enrollment: 39 (actual)

## Conditions studied

- Intraocular Melanoma
- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** IFA
- **BIOLOGICAL:** 6MHP
- **BIOLOGICAL:** GM-CSF

## Key facts

- **NCT ID:** NCT00089219
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2006-05
- **Final completion:** —
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2014-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089219, "Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00089219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*